Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. (Q50543805)
Jump to navigation
Jump to search
scientific article published on 6 July 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. |
scientific article published on 6 July 2017 |
Statements
Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy (English)
Béatrice Pignolet
Juan Carlos Triviño
Berta Miró
Miriam Mota
Alex Sanchez
Patrick Vermersch
Aurélie Ruet
Jérôme de Sèze
Pierre Labauge
Sandra Vukusic
Caroline Papeix
Laurent Almoyna
Ayman Tourbah
Thibault Moreau
Jean Pelletier
David Brassat
Manuel Comabella
Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference